GW Pharmaceuticals plc priced an underwritten public offering on the Nasdaq Global Market of 2,400,000 American depositary shares at $115 apiece.
The ADSs represent 28,800,000 ordinary shares of GW.
The U.K.-based company expects gross proceeds of about $276 million from the offering.
GW Pharmaceuticals granted underwriters a 30-day option to buy up to an additional 360,000 ADSs at the offering price.
The offering is expected to close Dec. 11.
Goldman Sachs & Co. LLC, Morgan Stanley, Bank of America Merrill Lynch and Cowen are acting as joint book-running managers for the offering.